ArticleAmerican journal of clinical dermatology2016
US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.
Article in American journal of clinical dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mesenchymal Stem Cells and Psoriasis: Systematic Review.International journal of molecular sciences · 2022Pooled it
- Biologics for Non-Cancer Dermatological Diseases: Analysis on China's Clinical Trial Registration Trend From 2016 to 2020.Frontiers in pharmacology · 2022Pooled it
- Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.The British journal of dermatology · 2021Trial
- Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.The Journal of dermatology · 2018Trial
- Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.Arthritis research & therapy · 2018Trial
- Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study.The Journal of dermatology · 2026Article
- Article
- Observational
- Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study.Drugs - real world outcomes · 2025Article
- Assessment of Primary Malignancy Risk after Initiation of Biologic Therapy in Patients with Psoriasis.JID innovations : skin science from molecules to population health · 2025Article
- Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study.Rheumatology and therapy · 2025Article
- Brand-to-brand nonmedical switching among interleukin-17 inhibitors or other biologics: Implications of a formulary change.Journal of managed care & specialty pharmacy · 2025Article
- Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients.Life (Basel, Switzerland) · 2025Article
- What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives.ACR open rheumatology · 2025Article
- Review
- Association of enthesitis with severity of psoriasis in psoriatic arthritis: an observational study.Rheumatology international · 2024Observational
- The impact of insurance status on psoriasis patients' healthcare-seeking behavior: a population-based study in the United States.BMC health services research · 2024Article
- Psychopathological Profile of Patients with Moderate-to-Severe Plaque Psoriasis and Its Correlation to DLQI: Results from a Prospective, Monocentric Clinical Study.Journal of clinical medicine · 2024Article
- Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.Dermatology and therapy · 2024Article
- Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.Clinical rheumatology · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP), a population-based survey of patients, dermatologists, and rheumatologists, was conducted for better understanding of the unmet needs of psoriasis and psoriatic arthritis (PsA) patients.
objectiveTo report results from US physicians and patients.
methodsAdults were contacted by household telephone, using random digit dialing, and asked to participate if they had ever been diagnosed with psoriasis or PsA. Physicians were identified through national databases and contacted through random sampling methods.
resultsIn the USA, 1005 patients, 101 dermatologists, and 100 rheumatologists were surveyed. PsA had been diagnosed in 270 patients (26.9%). Of those with psoriasis alone, fewer than 60% (versus 85.6% of PsA patients) had seen a healthcare provider within 12 months. Joint pain was reported by 51.8% of psoriasis patients without a diagnosis of PsA, and 37.6% of dermatologists cited their greatest challenge in managing PsA patients as being differentiating PsA from other arthritic diseases. Itching was reported by 36% of psoriasis patients versus 12% of dermatologists as the most important factor contributing to disease severity. Patients reported lower rates of current treatment than did dermatologists and rheumatologists. Conventional oral and biologic therapies were used by 24.9 and 17.7% of patients, respectively. Among patients who had received injectable biologics, treatment dissatisfaction was related to long-term safety/tolerability, injection-related anxiety/fear, and cost.
conclusionThis large, population-based survey identified unmet needs in the management of psoriasis and PsA patients in the USA, including assessment of disease severity, PsA diagnosis, undertreatment, and satisfaction with therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.